Understanding that Addiction Is a Brain Disorder Offers Help and Hope — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Understanding that Addiction Is a Brain Disorder Offers Help and Hope
Division of Addiction Research & Education, Center for Psychiatry, Medicine, & Primary Care (Office of the Provost), Western University Health Sciences, Pomona, USA
,
Department of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel, Israel
,
Division of Addiction Research & Education, Center for Psychiatry, Medicine, & Primary Care (Office of the Provost), Western University Health Sciences, Pomona, USA
,
Department of Psychiatry, South Texas Veteran Health Care System, Audie L. Murphy Memorial VA Hospital and Long School of Medicine, University of Texas Health Science Center, San Antonio, USA
,
Department of Psychology & Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions (BNNLA), Research Institute on Addictions, University at Buffalo, Buffalo, USA
,
Department of Psychiatry, Harvard School of Medicine, Cambridge, USA
,
Division of Personalized Medicine, The Kenneth Blum Behavioral & Neurogenetic Institute (Division of iVitalize, Inc.) Austin, USA
,
Department of Psychiatry, Washington University School of Medicine, St. Louis, USA
,
Department of Psychiatry, MT. Sinai School of Medicine, New York, USA
1 Division of Addiction Research & Education, Center for Psychiatry, Medicine, & Primary Care (Office of the Provost), Western University Health Sciences, Pomona, USA
2 Department of Molecular Biology and Adelson School of Medicine, Ariel University, Ariel, Israel
3 Division of Addiction Research & Education, Center for Psychiatry, Medicine, & Primary Care (Office of the Provost), Western University Health Sciences, Pomona, USA
4 Department of Psychiatry, South Texas Veteran Health Care System, Audie L. Murphy Memorial VA Hospital and Long School of Medicine, University of Texas Health Science Center, San Antonio, USA
5 Department of Psychology & Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions (BNNLA), Research Institute on Addictions, University at Buffalo, Buffalo, USA
6 Department of Psychiatry, Harvard School of Medicine, Cambridge, USA
7 Division of Personalized Medicine, The Kenneth Blum Behavioral & Neurogenetic Institute (Division of iVitalize, Inc.) Austin, USA
8 Department of Psychiatry, Washington University School of Medicine, St. Louis, USA
9 Department of Psychiatry, MT. Sinai School of Medicine, New York, USA
We refute the controversial statement that addiction is not a brain disorder. Extensive peer-reviewed studies support the underlying neurobiological and neurogenetic basis of addiction’s “disease model”. In the 70s and 80s, a few clinical scientists suggested that it is possible to use behavioral training to teach controlled drinking. However, this controversial model failed drastically and increased labeling and stigmatization. Additionally, it was unhelpful in the search for treatment. Instead, we assert that addiction is a neuropsychiatric disorder characterized by a recurring desire to continue taking substances despite harmful physical and mental consequences. Work from our laboratory in 1995 supported the Reward Deficiency Syndrome (RDS) concept based on a common neurogenetic mechanism (hypodopaminergia) that underlies all substance and non-substance addictions. Non-substance addictions include behaviors like pathological gambling, internet addiction, and mobile phone addiction. Certain impulsive and compulsive behaviors or the acute intake of psychoactive substances result in heightened dopaminergic activity, while the opposite, hypodopaminergia, occurs following chronic abuse. Patients with Substance Use Disorder (SUD) can have a genetic predisposition compounded by stress or other epigenetic insults that can impact recovery. Relapse will occur post-short-term recovery if dopaminergic dysfunction remains untreated. Addiction, a brain disorder, requires treatment with DNA-directed pro-dopamine regulation and rehabilitation.
Lewis, M. (2015) Biology of Desire: Why Addiction Is Not a Disease. Public Affairs, New York.
Zou, Z., Wang, H., d’Oleire Uquillas, F., Wang, X., Ding, J. and Chen, H. (2017) Definition of Substance and Non-Substance Addiction. Advances in Experimental Medicine and Biology, 1010, 21-41. https://doi.org/10.1007/978-981-10-5562-1_2
Gumbley, S.J. (2016) Recovery in the 21st Century: From Shame to Strength. Journal of Addictions Nursing, 27, 143-147. https://doi.org/10.1097/JAN.0000000000000125
Blum, K., Cull, J.G., Braverman, E.R. and Comings, D.E. (1996) Reward Deficiency Syndrome. American Scientist, 84, 132-145.
Smith, D.E. (2012) The Process Addictions and the New ASAM Definition of Addiction. Journal of Psychoactive Drugs, 44, 1-4. https://doi.org/10.1080/02791072.2012.662105
Kotyuk, E., Magi, A., Eisinger, A., Király, O., Vereczkei, A., Barta, C., Griffiths, M.D., Székely, A., Kokonyei, G., Farkas, J., et al. (2020) Co-Occurrences of Substance Use and Other Potentially Addictive Behaviors: Epidemiological Results from the Psychological and Genetic Factors of the Addictive Behaviors (PGA) Study. Journal of Behavioral Addictions, 9, 272-288. https://doi.org/10.1556/2006.2020.00033
Blum, K., Thompson, B., Demotrovics, Z., Femino, J., Giordano, J., Oscar-Berman, M., Teitelbaum, S., Smith, D.E., Roy, A.K., Agan, G., et al. (2015) The Molecular Neurobiology of Twelve Steps Program & Fellowship: Connecting the Dots for Recovery. Journal of Reward Deficiency Syndrome, 1, 46-64. https://doi.org/10.17756/jrds.2015-008
Kelly, J.F., Humphreys, K. and Ferri, M. (2020) Alcoholics Anonymous and Other 12-Step Programs for Alcohol Use Disorder. The Cochrane Database of Systematic Reviews, 3, Article No. CD012880. https://doi.org/10.1002/14651858.CD012880.pub2
Blum, K., Simpatico, T., Badgaiyan, R.D., Demetrovics, Z., Fratantonio, J., Agan, G., Febo, M. and Gold, M.S. (2015) Coupling Neurogenetics (GARS) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms. Journal of Reward Deficiency Syndrome, 1, 75-80. https://doi.org/10.17756/jrds.2015-012
Blum, K., Febo, M., Fried, L., Li, M., Dushaj, K., Braverman, E.R., McLaughlin, T., Steinberg, B. and Badgaiyan, R.D. (2017) Hypothesizing that Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated with “Dopamine Homeostasis” in Reward Deficiency Syndrome (RDS). Substance Use & Misuse, 52, 535-547. https://doi.org/10.1080/10826084.2016.1244551
Blum, K., Madigan, M.A., Fried, L., Braverman, E.R., Giordano, J. and Badgaiyan, R.D. (2017) Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD). Global Journal of Addiction & Rehabilitation Medicine, 1, Article ID: 555556. https://doi.org/10.19080/GJARM.2017.01.555556
Blum, K., Gold, M., Modestino, E.J., Baron, D., Boyett, B., Siwicki, D., Lott, L., Podesta, A., Roy, A.K., et al. (2018) Would Induction of Dopamine Homeostasis via Coupling Genetic Addiction Risk Score (GARS(R)) and Pro-Dopamine Regulation Benefit Benzodiazepine Use Disorder (BUD)? Journal of Systems and Integrative Neuroscience, 4. https://doi.org/10.15761/JSIN.1000196
Blum, K., Schoenthaler, S.J., Oscar-Berman, M., Giordano, J., Madigan, M.A., Braverman, E.R. and Han, D. (2014) Drug Abuse Relapse Rates Linked to Level of Education: Can We Repair Hypodopaminergic-Induced Cognitive Decline with Nutrient Therapy? The Physician and Sportsmedicine, 42, 130-145. https://doi.org/10.3810/psm.2014.05.2065
Blum, K., Modestino, E.J., Gondre-Lewis, M.C., Neary, J., Siwicki, D., Hauser, M., Barh, D., Steinberg, B. and Badgaiyan, R.D. (2017) Global Opioid Epidemic: Doomed to Fail without Genetically Based Precision Addiction Medicine (PAM): Lessons Learned from America. Precision Medicine, 2, 17-22.
Blum, K., Badgaiyan, R.D., Braverman, E.R., Dushaj, K., Li, M., Thanos, P.K., Demetrovics, Z. and Febo, M. (2016) Hypothesizing That, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term. Journal of Reward Deficiency Syndrome and Addiction Science, 2, 14-21. https://doi.org/10.17756/jrdsas.2016-023
Chen, T.J., Blum, K., Chen, A.L., Bowirrat, A., Downs, W.B., Madigan, M.A., Waite, R.L., Bailey, J.A., Kerner, M., Yeldandi, S., et al. (2011) Neurogenetics and Clinical Evidence for the Putative Activation of the Brain Reward Circuitry by a Neuroadaptagen: Proposing an Addiction Candidate Gene Panel Map. Journal of Psychoactive Drugs, 43, 108-127. https://doi.org/10.1080/02791072.2011.587393
Fried, L., Modestino, E.J., Siwicki, D., Lott, L., Thanos, P.K., Baron, D., Badgaiyan, R.D., Ponce, J.V., Giordano, J., Downs, B.W., et al. (2019) Hypodopaminergia and “Precision Behavioral Management” (PBM): It Is a Generational Family Affair. Current Pharmaceutical Biotechnology, 21, 528-541. https://doi.org/10.2174/1389201021666191210112108
Abijo, T., Blum, K. and Gondre-Lewis, M.C. (2019) Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) as a Function of Ethnicity: Relevance to Precision Addiction Medicine. Current Neuropharmacology, 18, 578-595. https://doi.org/10.2174/1570159X17666191118125702
Blum, K., Modestino, E.J., Neary, J., Gondre-Lewis, M.C., Siwicki, D., Moran, M., Hauser, M., Braverman, E.R., Baron, D., Steinberg, B., et al. (2018) Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis. Biomedical Journal of Scientific & Technical Research, 2, 1-4. https://doi.org/10.26717/BJSTR.2018.02.000738
Blum, K., Gondré-Lewis, M.C., Baron, D., Thanos, P.K., Braverman, E.R., Neary, J., Elman, I. and Badgaiyan, R.D. (2018) Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors. Frontiers in Psychiatry, 9, Article No. 548. https://doi.org/10.3389/fpsyt.2018.00548
Blum, K., Modestino, E.J., Lott, L., Siwicki, D., Baron, D., Howeedy, A. and Badgaiyan, R.D. (2018) Introducing “Precision Addiction Management (PAM(R))” As an Adjunctive Genetic Guided Therapy for Abusable Drugs in America. Open Access Journal of Behavioural Science & Psychology, 1, 1-4.
Baron, D., Blum, K., Chen, A., Gold, M. and Badgaiyan, R.D. (2018) Conceptualizing Addiction from an Osteopathic Perspective: Dopamine Homeostasis. The Journal of the American Osteopathic Association, 118, 115-118. https://doi.org/10.3389/fpsyt.2018.00548
Blum, K., Baron, D., Hauser, M., Henriksen, S., Thanos, P.K., Black, C., Siwicki, D., Modestino, E.J., Downs, B.W., Badgaiyan, S., et al. (2019) Americas’ Opioid/Psychostimulant Epidemic Would Benefit from General Population Early Identification of Genetic Addiction Risk Especially in Children of Alcoholics (COAs). Journal of Systems and Integrative Neuroscience, 5, 1-3. https://doi.org/10.15761/JSIN.1000212
Tabb, K., Lebowitz, M.S. and Appelbaum, P.S. (2019) Behavioral Genetics and Attributions of Moral Responsibility. Behavior Genetics, 49, 128-135. https://doi.org/10.1007/s10519-018-9916-0
Tabb, K., Lebowitz, M.S. and Appelbaum, P.S. (2019) Correction to: Behavioral Genetics and Attributions of Moral Responsibility. Behavior Genetics, 49, 347. https://doi.org/10.1007/s10519-018-9921-3
Wallace, J. (1990) Controlled Drinking, Treatment Effectiveness, and the Disease Model of Addiction: A Commentary on the Ideological Wishes of Stanton Peele. Journal of Psychoactive Drugs, 22, 261-284. https://doi.org/10.1080/02791072.1990.10472550
Maraz, A., Király, O. and Demetrovics, Z. (2015) Commentary on: Are We Overpathologizing Everyday Life? A Tenable Blueprint for Behavioral Addiction Research. The Diagnostic Pitfalls of Surveys: If You Score Positive on a Test of Addiction, You Still Have a Good Chance Not to Be Addicted. Journal of Behavioral Addictions, 4, 151-154. https://doi.org/10.1556/2006.4.2015.026
Blum, K., Gold, M., Demetrovics, Z., Archer, T., Thanos, P.K., Baron, D. and Badgaiyan, R.D. (2017) Substance Use Disorder a Bio-Directional Subset of Reward Deficiency Syndrome. Frontiers in Bioscience (Landmark Edition), 22, 1534-1548. https://doi.org/10.2741/4557
Prom-Wormley, E.C., Ebejer, J., Dick, D.M. and Bowers, M.S. (2017) The Genetic Epidemiology of Substance Use Disorder: A Review. Drug and Alcohol Dependence, 180, 241-259. https://doi.org/10.1016/j.drugalcdep.2017.06.040
Chaplin, T.M., Niehaus, C. and Goncalves, S.F. (2018) Stress Reactivity and the Developmental Psychopathology of Adolescent Substance Use. Neurobiology of Stress, 9, 133-139. https://doi.org/10.1016/j.ynstr.2018.09.002
Temmingh, H.S., van den Brink, W., Howells, F., Sibeko, G. and Stein, D.J. (2020) Methamphetamine Use and Antipsychotic-Related Extrapyramidal Side-Effects in Patients with Psychotic Disorders. Journal of Dual Diagnosis, 16, 208-217. https://doi.org/10.1080/15504263.2020.1714099
Hillemacher, T., Frieling, H., Buchholz, V., Hussein, R., Bleich, S., Meyer, C., John, U., Bischof, A. and Rumpf, H.J. (2015) Alterations in DNA-methylation of the Dopamine-Receptor 2 Gene Are Associated with Abstinence and Health Care Utilization in Individuals with a Lifetime History of pathologic Gambling. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 63, 30-34. https://doi.org/10.1016/j.pnpbp.2015.05.013
Febo, M., Blum, K., Badgaiyan, R.D., Baron, D., Thanos, P.K., Colon-Perez, L.M., Demortrovics, Z. and Gold, M.S. (2017) Dopamine Homeostasis: Brain Functional Connectivity in Reward Deficiency Syndrome. Frontiers in Bioscience (Landmark Edition), 22, 669-691. https://doi.org/10.2741/4509
Blum, K., Han, D., Modestino, E.J., Saunders, S., Roy, A.K., 3rd; Jacobs, W., Inaba, D.S., Baron, D., Oscar-Berman, M., Hauser, M., et al. (2018) A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/Naloxone. Substance Use & Misuse, 53, 220-229. https://doi.org/10.1080/10826084.2017.1400064
Pothos, E.N., Davila, V. and Sulzer, D. (1998) Presynaptic Recording of Quanta from Midbrain Dopamine Neurons and Modulation of the Quantal Size. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 18, 4106-4118. https://doi.org/10.1523/JNEUROSCI.18-11-04106.1998
Renard, J., Rosen, L.G., Loureiro, M., De Oliveira, C., Schmid, S., Rushlow, W.J. and Laviolette, S.R. (2017) Adolescent Cannabinoid Exposure Induces a Persistent Sub-Cortical Hyper-Dopaminergic State and Associated Molecular Adaptations in the Prefrontal Cortex. Cerebral Cortex (New York, N.Y.: 1991), 27, 1297-1310. https://doi.org/10.1093/cercor/bhv335
Blum, K., Morgan, J., Cadet, J.L., Baron, D., Carney, P.R., Khalsa, J., Badgaiyan, R.D. and Gold, M.S. (2021) Psychoactive Drugs like Cannabis-Induce Hypodopaminergic Anhedonia and Neuropsychological Dysfunction in Humans: Putative Induction of Dopamine Homeostasis via Coupling of Genetic Addiction Risk Severity (GARS) Testing and Precision Pro-Dopamine Regulation (KB220). Neurology (ECronicon), 13, 86-92.
Blum, K., Khalsa, J., Cadet, J.L., Baron, D., Bowirrat, A., Boyett, B., Lott, L., Brewer, R., Gondré-Lewis, M., Bunt, G., et al. (2021) Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis. Frontiers in Psychiatry, 12, Article ID: 623403. https://doi.org/10.3389/fpsyt.2021.623403
Blum, K., Bowirrat, A., Baron, D., Lott, L., Ponce, J.V., Brewer, R., Siwicki, D., Boyett, B., et al. (2019) Biotechnical Development of Genetic Addiction Risk Score (GARS) and Selective Evidence for Inclusion of Polymorphic Allelic Risk in Substance Use Disorder (SUD). Journal of Systems and Integrative Neuroscience, 6. https://doi.org/10.15761/JSIN.1000221
Chen, R., Ferris, M.J. and Wang, S. (2020) Dopamine D2 Autoreceptor Interactome: Targeting the Receptor Complex as a Strategy for Treatment of Substance Use Disorder. Pharmacology & Therapeutics, 213, Article ID: 107583. https://doi.org/10.1016/j.pharmthera.2020.107583
Fedota, J.R. and Stein, E.A. (2015) Resting-State Functional Connectivity and Nicotine Addiction: Prospects for Biomarker Development. Annals of the New York Academy of Sciences, 1349, 64-82. https://doi.org/10.1111/nyas.12882
Febo, M., Blum, K., Badgaiyan, R.D., Perez, P.D., Colon-Perez, L.M., Thanos, P.K., Ferris, C.F., Kulkarni, P., Giordano, J., Baron, D., et al. (2017) Enhanced Functional Connectivity and Volume between Cognitive and Reward Centers of Naive Rodent Brain Produced by Pro-Dopaminergic Agent KB220Z. PLOS ONE, 12, e0174774. https://doi.org/10.1371/journal.pone.0174774
Blum, K., Liu, Y., Wang, W., Wang, Y., Zhang, Y., Oscar-Berman, M., Smolen, A., Febo, M., Han, D., Simpatico, T., et al. (2015) rsfMRI Effects of KB220Z on Neural Pathways in Reward Circuitry of Abstinent Genotyped Heroin Addicts. Postgraduate Medicine, 127, 232-241. https://doi.org/10.1080/00325481.2015.994879
Blum, K., Gondre-Lewis, M., Steinberg, B., Elman, I., Baron, D., Modestino, E.J., Badgaiyan, R.D. and Gold, M.S. (2018) Our Evolved Unique Pleasure Circuit Makes Humans Different from Apes: Reconsideration of Data Derived from Animal Studies. Journal of Systems and Integrative Neuroscience, 4, 1-7. https://doi.org/10.15761/JSIN.1000191
Thanos, P.K., Volkow, N.D., Freimuth, P., Umegaki, H., Ikari, H., Roth, G., Ingram, D.K. and Hitzemann, R. (2001) Overexpression of Dopamine D2 Receptors Reduces Alcohol Self-Administration. Journal of Neurochemistry, 78, 1094-1103. https://doi.org/10.1046/j.1471-4159.2001.00492.x
Heyman, G.M. (2013) Addiction and Choice: Theory and New Data. Frontiers in Psychiatry, 4, Article No. 31. https://doi.org/10.3389/fpsyt.2013.00031
Iyo, M. and Yamasaki, T. (1993) The Detection of Age-Related Decrease of Dopamine D1, D2 and Serotonin 5-HT2 Receptors in Living Human Brain. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 17, 415-421. https://doi.org/10.1016/0278-5846(93)90075-4
Heilig, M., MacKillop, J., Martinez, D., Rehm, J., Leggio, L. and Vanderschuren, L. (2021) Addiction as a Brain Disease Revised: Why It Still Matters, and the Need for Consilience. Neuropsycho-pharmacology: Official Publication of the American College of Neuropsychopharmacology, 46, 1715-1723. https://doi.org/10.1038/s41386-020-00950-y
Evans-Polce, R.J., Castaldelli-Maia, J.M., Schomerus, G. and Evans-Lacko, S.E. (2015) The Downside of Tobacco Control? Smoking and Self-Stigma: A Systematic Review. Social Science & Medicine, 145, 26-34. https://doi.org/10.1016/j.socscimed.2015.09.026